The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Cancer, Clots and Consensus: New Understanding of an Old Problem
Open accessAbstract
Long before reaching our current understanding of the complex relationship between malignancy and the elements of the coagulation system, it was recognized that patients with cancer were at increased risk for thrombosis. Armand Trousseau first described patients with thrombophlebitis as the presenting sign of a visceral malignancy, later known as Trousseau’s syndrome, which he attributed to a special alteration of the blood. Increased risk of thrombosis is associated with alterations in normal blood flow, injury to the vascular endothelium, and alterations in the constitution of blood, referred to as Virchow’s triad (Table 1). While the resulting hypercoagulable state rarely results in overt disseminated intravascular coagulation, virtually all patients with active malignancy demonstrate some degree of activation of the coagulation cascade. Today, it is recognized that thrombosis and cancer are linked by multiple pathophysiological mechanisms and that tumor biology and coagulation processes are integrally connected (Fig 1). The underlying biologic factors associated with the increased risk of thrombosis in patients with cancer include the activation of thrombin and fibrin formation both directly by the release of procoagulants by tumor cells and indirectly by the activation of endothelial cells, leukocytes, and platelets by cytokines and the production of a factor X-activating cysteine protease, mucinous glycoproteins, and circulating tissue factor–bearing microparticles. The molecular and genomic factors at the interface between malignant cell behavior and the hypercoagulable state in the patient with cancer are discussed in the articles by Boccaccio and Comoglio and by Kasthuri et al in this special issue of the Journal of Clinical Oncology. Venous thromboembolism (VTE) may indicate an occult cancer, may represent a complication of a known malignancy, or complicate hospitalization, surgery, or various systemic cancer treatments. VTE, including deep-vein thrombosis (DVT) and pulmonary embolism (PE), is a serious and potentially life-threatening disorder representing the second leading cause of death in hospitalized patients with cancer, although often demonstrated only at autopsy. In addition, the occurrence of VTE may interrupt needed cancer treatment, even as the use of anticoagulants may result in serious bleeding complications. In addition to the human cost, the economic burden of VTE in patients with cancer is substantial with the average cost of hospitalization for DVT estimated at more than $20,000 and one fourth of patients with cancer with VTE requiring readmission as a result of bleeding or a recurrent VTE. Fortunately, there has been considerable progress not only in our basic understanding of the underlying pathophysiology, but also in the diagnosis of VTE and the options available for the treatment and prevention of thrombosis in patients with cancer. Current guidelines recommend primary prophylaxis in both surgical and medical hospitalized patients and for highly selected ambulatory patients with cancer. The development and validation of clinical risk models and the identification of new biomarkers for the selection of patients at increased risk for VYE represents an active area of research. Likewise, the potential impact of anticoagulation on cancer growth, invasion, metastases, and angiogenesis as well as overall survival continues to be actively investigated. It is essential that the results of ongoing research on underlying mechanisms as well as the optimal treatment Procoagulant activities Fibrinolytic activities
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Thrombus Formation
Furie, B., & Furie, B. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801082 · Cited by 1,926
Antithrombotic Therapy for Venous Thromboembolic Disease
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.401s · Cited by 1,249 · cited 1×
“cancer as well as the prevention of recurrent VTE (secondary prophylaxis) continues to be investigated.(65) The impact of different antico-”
BackgroundCatheter-Associated Thrombosis in Patients With Malignancy
Shivakumar, S. P., Anderson, D. R., & Couban, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6126 · Cited by 77
Cited by
Contribution of platelets to tumour metastasis
Gay, L. J., & Felding-Habermann, B. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3004 · Cited by 1,645
Cancer-associated venous thromboembolism: Burden, mechanisms, and management
Ay, C., Pabinger, I., & Cohen, A. T. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-08-0615 · Cited by 496
Labelle, M., & Hynes, R. O. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0329 · Cited by 486
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
High D-dimer levels are associated with poor prognosis in cancer patients
Ay, C., Dunkler, D., Pirker, R., Thaler, J., Quehenberger, P., Wagner, O., Zielinski, C., & Pabinger, I. (2012) · Haematologica · doi:10.3324/haematol.2011.054718 · Cited by 340
Metadata
- Authors
- Lyman, G. H., & Khorana, A. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-10-10
- Volume
- 27
- Issue
- 29
- Pages
- 4821-4826
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2069449301
- Cited by
- 190
- References
- 3
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer, Clots and Consensus: New Understanding of an Old Problem. https://app.cochat.ai/papers/10.1200/jco.2009.22.3032
- The paper
- Lyman, G. H., & Khorana, A. A. (2009). Cancer, Clots and Consensus: New Understanding of an Old Problem. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.22.3032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.